TriSalus Life Sciences (TLSI) Appoints Riad Salem to its Board

TriSalus Life Sciences® Inc. (Nasdaq: TLSI) has announced the addition of Riad Salem, M.D., to its Scientific Advisory Board (SAB).

Dr. Salem is the Chief of Interventional Radiology, and a Professor of Radiology, Surgery, and Medicine in Chicago. Mary Szela, Chief Executive Officer and President of TriSalus, stated, “We are thrilled to welcome Dr. Salem to our SAB. His pioneering work in radiological research and leadership in developing innovative treatments for liver cancer and other malignancies will be invaluable as we further our mission. Dr. Salem led the LEGACY study, demonstrating y90 delivers high response rates and significant improvements in response duration and survival. His dedication to advancing life-prolonging therapies and empowering physicians through data-driven decisions aligns perfectly with our goals. His expertise will be crucial as we advance our Pressure Enabled Drug Delivery™ (PEDD™) technology and nelitolimod, a TLR9 agonist, to enhance outcomes for patients with complex conditions.

Dr. Salem’s role will be central as we roll out our DELIVER program, a comprehensive clinical initiative designed to provide robust data and further support for the PEDD method and nelitolimod in challenging patient populations.”

Dr. Salem expressed his enthusiasm about his new role, stating, “I am excited to join the TriSalus SAB. Despite recent advances in treatment, there remains a significant need for improved treatments, particularly for complex liver and pancreatic cancer cases. I look forward to working with TriSalus to investigate their novel immunotherapeutic agent, nelitolimod, and their TriNav® drug delivery technology to enhance treatment outcomes for these challenging patient populations.”

Dr. Riad Salem is renowned for his contributions to image-guided techniques in oncology. He earned his medical degree from McGill University, completed his residency at George Washington University, and undertook a fellowship at the University of Pennsylvania.

For more information about TriSalus Life Sciences and its innovative technologies, please visit www.trisaluslifesciences.com.

You May Also Be Interested In

• Kimbell Royalty closes $221.2M mineral rights acquisition
• Home Depot expands executive roles, grants $500K in restricted stock
• Nu Skin EVP of global sales takes medical leave